Literature DB >> 19670444

Soluble endoglin modulates aberrant cerebral vascular remodeling.

Yongmei Chen1, Qi Hao, Helen Kim, Hua Su, Michelle Letarte, S Ananth Karumanchi, Michael T Lawton, Nicholas M Barbaro, Guo-Yuan Yang, William L Young.   

Abstract

OBJECTIVE: Brain arteriovenous malformations (AVMs) are an important cause of neurological morbidity in young adults. The pathophysiology of these lesions is poorly understood. A soluble form of endoglin (sEng) has been shown to cause endothelial dysfunction and induce preeclampsia. We tested if sEng would be elevated in brain AVM tissues relative to epilepsy brain tissues, and also investigated whether sEng overexpression via gene transfer in the mouse brain would induce vascular dysplasia and associated changes in downstream signaling pathways.
METHODS: Expression levels of sEng in surgical specimens were determined by Western blot assay and enzyme-linked immunosorbent assay. Vascular dysplasia, levels of matrix metalloproteinase (MMP), and oxidative stress were determined by immunohistochemistry and gelatin zymography.
RESULTS: Brain AVMs (n = 33) had higher mean sEng levels (245 +/- 175 vs 100 +/- 60, % of control, p = 0.04) compared with controls (n = 8), as determined by Western blot. In contrast, membrane-bound Eng was not significantly different (108 +/- 79 vs 100 +/- 63, % of control, p = 0.95). sEng gene transduction in the mouse brain induced abnormal vascular structures. It also increased MMP activity by 490 +/- 30% (MMP-9) and 220 +/- 30% (MMP-2), and oxidants by 260 +/- 20% (4-hydroxy-2-nonenal) at 2 weeks after injection, suggesting that MMPs and oxidative radicals may mediate sEng-induced pathological vascular remodeling.
INTERPRETATION: The results suggest that elevated sEng may play a role in the generation of sporadic brain AVMs. Our findings may provide new targets for therapeutic intervention for patients with brain AVMs. Ann Neurol 2009;66:19-27.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19670444      PMCID: PMC2773229          DOI: 10.1002/ana.21710

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  36 in total

1.  Analysis of several endoglin mutants reveals no endogenous mature or secreted protein capable of interfering with normal endoglin function.

Authors:  M E Paquet; N Pece-Barbara; S Vera; U Cymerman; A Karabegovic; C Shovlin; M Letarte
Journal:  Hum Mol Genet       Date:  2001-06-15       Impact factor: 6.150

2.  Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1.

Authors:  A Bourdeau; U Cymerman; M E Paquet; W Meschino; W C McKinnon; A E Guttmacher; L Becker; M Letarte
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  Cerebral vascular abnormalities in a murine model of hereditary hemorrhagic telangiectasia.

Authors:  Junichiro Satomi; Richard J Mount; Mourad Toporsian; Andrew D Paterson; M Christopher Wallace; Robert V Harrison; Michelle Letarte
Journal:  Stroke       Date:  2003-01-30       Impact factor: 7.914

Review 4.  Vascular morphogenesis: tales of two syndromes.

Authors:  Douglas A Marchuk; Sudha Srinivasan; Teresa L Squire; Jon S Zawistowski
Journal:  Hum Mol Genet       Date:  2003-04-01       Impact factor: 6.150

5.  Analysis of endoglin expression in normal brain tissue and in cerebral arteriovenous malformations.

Authors:  S Matsubara; A Bourdeau; K G terBrugge; C Wallace; M Letarte
Journal:  Stroke       Date:  2000-11       Impact factor: 7.914

6.  Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia.

Authors:  H Narumiya; Y Zhang; C Fernandez-Patron; L J Guilbert; S T Davidge
Journal:  Hypertens Pregnancy       Date:  2001       Impact factor: 2.108

7.  Characteristics of brain arteriovenous malformations with coexisting aneurysms: a comparison of two referral centers.

Authors:  Alexander X Halim; Vineeta Singh; S Claiborne Johnston; Randall T Higashida; Christopher F Dowd; Van V Halbach; Michael T Lawton; Daryl R Gress; Charles E McCulloch; William L Young
Journal:  Stroke       Date:  2002-03       Impact factor: 7.914

8.  Differential gene expression in human cerebrovascular malformations.

Authors:  Robert Shenkar; J Paul Elliott; Katrina Diener; Judith Gault; Ling-Jia Hu; Randall J Cohrs; Tzulip Phang; Lawrence Hunter; Robert E Breeze; Issam A Awad
Journal:  Neurosurgery       Date:  2003-02       Impact factor: 4.654

9.  Common variants in interleukin-1-Beta gene are associated with intracranial hemorrhage and susceptibility to brain arteriovenous malformation.

Authors:  Helen Kim; Pirro G Hysi; Ludmila Pawlikowska; Annie Poon; Esteban González Burchard; Jonathan G Zaroff; Stephen Sidney; Nerissa U Ko; Achal S Achrol; Michael T Lawton; Charles E McCulloch; Pui-Yan Kwok; William L Young
Journal:  Cerebrovasc Dis       Date:  2008-12-18       Impact factor: 2.762

10.  Differential levels of soluble endoglin (CD105) in myeloid malignancies.

Authors:  Luana Calabrò; Ester Fonsatti; Giacomo Bellomo; Andrea Alonci; Francesca Colizzi; Luca Sigalotti; Maresa Altomonte; Caterina Musolino; Michele Maio
Journal:  J Cell Physiol       Date:  2003-02       Impact factor: 6.384

View more
  21 in total

1.  Perlecan domain V is upregulated in human brain arteriovenous malformation and could mediate the vascular endothelial growth factor effect in lesional tissue.

Authors:  Michael P Kahle; Boyeon Lee; Tony Pourmohamad; Austin Cunningham; Hua Su; Helen Kim; Yongmei Chen; Charles E McCulloch; Nicholas M Barbaro; Michael T Lawton; William L Young; Gregory J Bix
Journal:  Neuroreport       Date:  2012-07-11       Impact factor: 1.837

Review 2.  Lacritin and other autophagy associated proteins in ocular surface health.

Authors:  Roy Karnati; Venu Talla; Katherine Peterson; Gordon W Laurie
Journal:  Exp Eye Res       Date:  2015-08-25       Impact factor: 3.467

Review 3.  Endoglin in liver fibrogenesis: Bridging basic science and clinical practice.

Authors:  Steffen K Meurer; Muhammad Alsamman; David Scholten; Ralf Weiskirchen
Journal:  World J Biol Chem       Date:  2014-05-26

4.  Endothelial signaling and the molecular basis of arteriovenous malformation.

Authors:  Deepak Atri; Bruno Larrivée; Anne Eichmann; Michael Simons
Journal:  Cell Mol Life Sci       Date:  2013-09-28       Impact factor: 9.261

5.  An early venous abnormality: a potential cause of arteriovenous malformation recurrence.

Authors:  David Weingarten; Sean Pakbaz; Aaron Cho; Hoi Sang U
Journal:  BMJ Case Rep       Date:  2012-09-11

Review 6.  Brain arteriovenous malformation modeling, pathogenesis, and novel therapeutic targets.

Authors:  Wanqiu Chen; Eun-Jung Choi; Cameron M McDougall; Hua Su
Journal:  Transl Stroke Res       Date:  2014-04-12       Impact factor: 6.829

7.  A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH).

Authors:  Romuald Girard; Yan Li; Agnieszka Stadnik; Robert Shenkar; Nicholas Hobson; Sharbel Romanos; Abhinav Srinath; Thomas Moore; Rhonda Lightle; Abdallah Shkoukani; Amy Akers; Timothy Carroll; Gregory A Christoforidis; James I Koenig; Cornelia Lee; Kristina Piedad; Steven M Greenberg; Helen Kim; Kelly D Flemming; Yuan Ji; Issam A Awad
Journal:  Neurosurgery       Date:  2021-02-16       Impact factor: 4.654

8.  Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients.

Authors:  Ana M Blázquez-Medela; Luis García-Ortiz; Manuel A Gómez-Marcos; José I Recio-Rodríguez; Angel Sánchez-Rodríguez; José M López-Novoa; Carlos Martínez-Salgado
Journal:  BMC Med       Date:  2010-12-20       Impact factor: 8.775

Review 9.  TGFβ signaling and cardiovascular diseases.

Authors:  Evangelia Pardali; Peter Ten Dijke
Journal:  Int J Biol Sci       Date:  2012-01-01       Impact factor: 6.580

10.  Hypoxia-inducible factor-1α and vascular endothelial growth factor in the cardioprotective effects of intermittent hypoxia in rats.

Authors:  Zhang Wang; Liang-Yi Si
Journal:  Ups J Med Sci       Date:  2013-02-26       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.